Novartis received breakthrough therapy designation from the FDA for ianalumab, a monoclonal antibody aimed at treating Sjögren’s disease.
Ianalumab works by depleting B cells and blocking BAFF-R signaling, which inhibits B-cell activation and survival. The drugmaker, based in Switzerland, plans to begin global regulatory submissions in early 2026, according to a Jan. 16 company news release. If approved, ianalumab would become the first targeted treatment for Sjögren’s, a systemic autoimmune disorder with no approved therapies.
The FDA’s designation is based on results from two global phase 3 trialsthat demonstrated clinically meaningful benefits, reduced disease burden and a favorable safety profile. Ianalumab previously received fast track designation in 2016, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
